Results 221 to 230 of about 97,019 (266)

Contribution of Apolipoprotein L1 (APOL1) Risk Alleles to Kidney Disease in West Africa: an opportunity for treatment. [PDF]

Ghana Med J
Adu D.
europepmc   +1 more source

Interpreting Triglycerides: A National Cross‐Sectional Review of Laboratory Reporting Practices

Diabetes, Obesity and Metabolism, EarlyView.
Jeff R. Ma, Sean Tan, Gerald F. Watts, Nick S. R. Lan, Robert Hungerford, Peter J. Psaltis, Jessica A. Marathe, Stephen J. Nicholls, Adam J. Nelson   +8 more
wiley   +1 more source

HDL-C and apolipoprotein A-I are independently associated with skeletal muscle mitochondrial function in healthy humans.

Am J Physiol Heart Circ Physiol
Giacona JM, Petric UB, Kositanurit W, Wang J, Saldanha S, Young BE, Khan G, Connelly MA, Smith SA, Rohatgi A, Vongpatanasin W.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Apolipoprotein A-I

Journal of Pediatric Gastroenterology and Nutrition, 1990
The apolipoprotein (apo) A‐I:B ratio and the apo B concentration were determined by radial immunodiffusion in dried blood spot samples from 1,767 10‐and 11‐year‐old children. Children with either apo A‐I:B ratios below the first percentile or apo B levels above the 99th were recalled and plasma lipid and apolipoprotein profiles were determined for both
Tomas Sveger, Göran Fex, Carl‐Erik Flodmark, Thomas Kjellström, Nils Borgfors   +4 more
openaire   +1 more source

The Immunochemical Determination of Apolipoprotein A, Total Apolipoprotein A-I and ‘Free’ Apolipoprotein A-I in Serum of Patients on Chronic Haemodialysis

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1984
We have determined by radial immunodiffusion the apolipoprotein A content of undelipidated serum samples from 30 patients on chronic haemodialysis and 28 controls using an antiserum against high density lipoprotein (anti-apolipoprotein A). We found that the patients had lower concentrations of apolipoprotein A than the controls.
D O, Gebhardt, I M, Schicht, L C, Paul
openaire   +2 more sources

Apolipoprotein A-I mimetic peptides

Current Opinion in Lipidology, 2010
To review published data related to the potential applicability of apolipoprotein A-I mimetic peptides.Despite a wealth of information on HDL-C levels and risk for cardiovascular disease (CVD), little evidence is present to suggest that raising HDL-C levels per se will result in CVD risk reduction.
G K, Hovingh, Andrea E, Bochem, John J P, Kastelein   +2 more
openaire   +2 more sources

Apolipoprotein A-I in Liver Disease

Scandinavian Journal of Gastroenterology, 1987
Apolipoprotein A-I and high-density lipoprotein concentrations in the plasma of patients with liver disease have been found to be either normal or lower than normal. In this study the apolipoprotein A-I concentration was measured in the plasma of 19 patients with cholestatic liver disease and 21 patients with noncholestatic liver disease.
C H, Florén, J, Franzén, J J, Albers
openaire   +2 more sources

Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome

Current Opinion in Lipidology, 2007
The goal of identifying subjects with metabolic syndrome is to detect those at higher risk of developing cardiovascular disease. Evidence continues to accumulate as to the superiority of apolipoprotein B and apolipoprotein A-I over the conventional lipoprotein lipids as markers of vascular risk.
Allan D, Sniderman, May, Faraj
openaire   +2 more sources

Apolipoproteins A‐I and B in Obese Children

Journal of Pediatric Gastroenterology and Nutrition, 1989
Body mass index (BMI), the distribution of fat, birth weight, physical fitness, apolipoproteins (apo) A‐I and B, total cholesterol (TC), and high‐density lipoprotein cholesterol (HDLC) were studied in 38 obese 10− to 11‐year‐olds in comparison to 52 age‐matched controls.
T, Sveger, C E, Flodmark, G, Fex, N C, Henningsen   +3 more
openaire   +2 more sources

The promise of apolipoprotein A-I mimetics

Current Opinion in Endocrinology, Diabetes & Obesity, 2010
Synthetic high-density lipoprotein (HDL) and apolipoprotein (apo) A-I mimetic peptides emulate many of the atheroprotective biological functions attributed to HDL and can modify atherosclerotic disease processes. Administration of these agents as HDL replacement or modifying therapy has tremendous potential of providing new treatments for ...
openaire   +2 more sources